Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene’s psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday.
Source:: Reuters – Business News
Newswire
- [ June 26, 2025 ] Hoth Therapeutics (NASDAQ: HOTH) HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects Newsmakers
- [ June 26, 2025 ] Lottery.com (NASDAQ: LTRY) Announces $10 Million Acquisition of GXR World Sports Assets to Power Global Launch of Sports.com Super App Newsmakers
- [ June 25, 2025 ] Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease. Healthcare
- [ June 24, 2025 ] Lottery.com (NASDAQ: LTRY) Appoints Tim Scoffham as CEO to Lead Global Expansion of Sports.com Media and Lottery.com International Newsmakers
- [ June 23, 2025 ] Lottery.com (NASDAQ: LTRY) Appoints Acclaimed Actor and Director Tamer Hassan as President of Sports.com Studios Newsmakers
- [ June 23, 2025 ] Core Gaming (NASDAQ: SYTA) Showcases Technological Strength as AI App Gains Traction Newsmakers
- [ June 23, 2025 ] Lottery.com (NASDAQ: LTRY) Regains Nasdaq Compliance as Stock Trading Activity Soars Newsmakers
- [ June 23, 2025 ] Hoth Therapeutics (NASDAQ: HOTH) to host KOL Event Spotlighting HT-001, Novel Therapy Newsmakers
- [ June 16, 2025 ] Sports.com (NASDAQ: LTRY) Enters Strategic Sponsorship with Racing Women to Accelerate the Future of Female Motorsport Newsmakers
- [ June 16, 2025 ] Lottery.com (NASDAQ: LTRY) and Sports.com Featured at Gateway with Triple-Driver Sponsorship Across IndyCar and IndyNXT Newsmakers
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.